[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627271":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":22,"centralContacts":31,"locations":37,"responsibleParty":52,"collaborators":22,"id":55,"slug":22,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":22,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":22,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":22,"overallStatus":74,"whyStopped":22,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Fudan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Conversion Therapy","EXPERIMENTAL","Conversion Therapy (≤6 months) Fruquintinib: 4 mg orally once daily, Days 1-21, every 4 weeks mFOLFOX6: Oxaliplatin 85 mg\u002Fm² IV q2w Leucovorin 400 mg\u002Fm² IV q2w 5-FU 400 mg\u002Fm² IV bolus Day 1 5-FU 1200 mg\u002Fm²\u002Fday continuous IV infusion Days 2-3 Serplulimab: 200 mg IV Day 1, q2w Fruquintinib must be stopped ≥2 weeks prior to surgery and resumed ≥4 weeks postoperatively.",[13,14,15],"Drug: Serplulimab","Drug: Fruquintinib","Drug: mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)",[17,23,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Serplulimab","Serplulimab: 200 mg IV Day 1, q2w",[9],null,{"type":18,"name":24,"description":25,"armGroupLabels":26,"otherNames":22},"Fruquintinib","Fruquintinib: 4 mg orally once daily, Days 1-21, every 4 weeks",[9],{"type":18,"name":28,"description":29,"armGroupLabels":30,"otherNames":22},"mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)","Oxaliplatin 85 mg\u002Fm² IV q2w Leucovorin 400 mg\u002Fm² IV q2w 5-FU 400 mg\u002Fm² IV bolus Day 1 5-FU 1200 mg\u002Fm²\u002Fday continuous IV infusion Days 2-3",[9],[32],{"name":33,"role":34,"phone":35,"phoneExt":22,"email":36},"Ye Xu","CONTACT","+86 18017312565","yexu@shmu.edu.cn",[38],{"facility":39,"status":22,"city":40,"state":41,"zip":22,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Fudan University Shanghai Cancer Center","Shanghai","Xuhui","China","CN",{"type":45,"coordinates":46},"Point",[47,48],121.45806,31.22222,{"lat":48,"lon":47},[51],{"name":33,"role":34,"phone":35,"phoneExt":22,"email":36},{"type":53,"investigatorFullName":33,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"SPONSOR_INVESTIGATOR","Professor","100627271",false,"NCT07446465","FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR\u002FMSS Colorectal Cancer","Exploratory Clinical Study of FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR\u002FMSS Colorectal Cancer","Inclusion Criteria:\n\n* Age 18-75 years;\n* Histologically confirmed adenocarcinoma of colorectal cancer, initially unresectable locally advanced or metastatic\u002Frecurrent disease;\n* Expected survival ≥12 weeks;\n* No prior systemic antitumor therapy for colorectal cancer;\n* Confirmed pMMR by IHC or MSS\u002FMSI-L by PCR or NGS;\n* ECOG PS 0-1;\n* At least one measurable lesion per RECIST v1.1;\n* Adequate organ and bone marrow function;\n* Controlled viral hepatitis status as specified;\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Prior immune checkpoint inhibitor therapy;\n* CNS or leptomeningeal metastases;\n* Uncontrolled cardiovascular disease or hypertension;\n* Active autoimmune disease requiring systemic therapy;\n* Active infection including tuberculosis;\n* Recent major surgery;\n* Pregnancy or lactation;\n* Any condition deemed by investigators to compromise safety or study compliance.","ALL","18 Years","75 Years",{"count":65,"type":66},42,"ESTIMATED","INTERVENTIONAL",[69],"PHASE4","To evaluate the efficacy and safety of immune checkpoint inhibitor-based combination therapy with targeted therapy and chemotherapy in patients with locally advanced unresectable or metastatic colorectal cancer.",[72,73],"Colorectal Cancer (Locally Advanced or Metastatic)","Colorectal Cancer Microsatellite Stable (MSS)","NOT_YET_RECRUITING","2026-02-28",{"date":77,"type":78},"2026-03-03","ACTUAL",{"date":80,"type":66},"2026-03-01",{"date":82,"type":66},"2027-01-31",{"name":33,"class":6},1]